LDL-C levels\\xa0<25 or\\xa0<15 mg/dl on alirocumab were not associated with an increase in overall treatment-emergent adverse event rates or neurocognitive events, although cataract incidence appeared to be\\xa0increased\\xa0in the group achieving LDL-C levels\\xa0<25 mg/dl.